Pulse Biosciences公司近日宣布,其Npulse™ Vybrance™系统在针对良性甲状腺结节消融的首次人体临床耐久性研究中取得了积极数据。该研究旨在评估该技术在治疗良性甲状腺结节方面的长期效果与安全性。
研究结果显示,Npulse™ Vybrance™系统在消融良性甲状腺结节方面展现出显著的持久性,为患者提供了一种潜在的非侵入性治疗选择。这一进展标志着公司在医疗技术领域的创新突破,有望为甲状腺疾病治疗带来新的解决方案。
Pulse Biosciences公司近日宣布,其Npulse™ Vybrance™系统在针对良性甲状腺结节消融的首次人体临床耐久性研究中取得了积极数据。该研究旨在评估该技术在治疗良性甲状腺结节方面的长期效果与安全性。
研究结果显示,Npulse™ Vybrance™系统在消融良性甲状腺结节方面展现出显著的持久性,为患者提供了一种潜在的非侵入性治疗选择。这一进展标志着公司在医疗技术领域的创新突破,有望为甲状腺疾病治疗带来新的解决方案。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.